The Form 4 filing, an SEC report of insider stock trades, was filed on November 16, 2026. The sale took place on November 12, four days before the filing date.
The report lists Martine Zimmermann as a director of Ligand Pharmaceuticals (LGND). The company is in the healthcare sector's biotechnology industry.
Transaction details
| Transaction | |
|---|---|
| Date of Earliest Transaction | 2026-11-12 |
| Date of Latest Transaction | 2026-11-12 |
| Buy/Sell | sell |
| Transaction Count | 1 |
| Shares Transacted | 2,000 |
| Price | $318.17 |
| Total Transaction Value | $636,336.20 |
| Insider | |
| Ticker Symbol | LGND |
| Company | LIGAND PHARMACEUTICALS INC |
| Insider Name | Zimmermann Martine |
| Insider Title | Director |
| Sector - Industry | Healthcare - Biotechnology |
| Holdings | |
| Total Shares Owned After Transaction | 1,782 |
| Position Size Change | 52.88% |
| Filing | |
| Filing Date | 2026-11-16 |
| SEC Link | View filing |
FAQ
What type of transaction is this?
This was a sale of 2,000 LGND shares, reported under transaction code S. The record lists one transaction by Martine Zimmermann.
What was the average price of the transaction?
The average sale price was $318.1681 per share. Rounded to cents, that is $318.17 per share.
How did this transaction affect the insider's holdings?
Martine Zimmermann sold 2,000 shares and reported 1,782 shares owned afterward. The sale represented 52.88% of the shares held before the trade, based on this reported balance. Shares remained in that balance after the sale.
What's the total transaction value?
The total transaction value was $636,336.20. That amount covers the single reported sale of 2,000 shares.
Are there any special circumstances around this transaction?
The available transaction information did not identify a special arrangement. Footnote text was not provided, so further details about the sale's terms and circumstances remain unknown.
For research purposes only; not investment advice.